Group 1 - The core point of the article highlights that Luoxin Pharmaceutical reported a decrease in the number of shareholders, with a total of 43,927 shareholders as of October 31, which is a reduction of 4,377 shareholders compared to the previous period, reflecting a month-on-month decline of 9.06% [2] - The closing price of Luoxin Pharmaceutical was 5.40 yuan, remaining flat, with a cumulative decline of 1.46% in stock price since the concentration of shares began, showing 5 days of increases and 8 days of decreases during this period [2] - The company's third-quarter report indicates that for the first three quarters, it achieved an operating income of 1.723 billion yuan, a year-on-year decrease of 8.37%, while net profit reached 22.93 million yuan, a year-on-year increase of 108.64%, with basic earnings per share of 0.0216 yuan and a weighted average return on equity of 1.62% [2]

Core Viewpoint - The company, Luoxin Pharmaceutical (002793), reported that as of October 31, 2025, the total number of shareholders is 43,927 [1] Summary by Relevant Sections - Shareholder Information - As of October 31, 2025, the total number of shareholders for Luoxin Pharmaceutical is 43,927 [1]

Group 1 - The core point of the article is that Luoxin Pharmaceutical announced the release of stock pledges by its controlling shareholder, Shandong Luoxin Holdings Co., Ltd. [1] - The number of shares released from pledge is 36,020,000 shares, which accounts for 15.20% of the shares held by the controlling shareholder [1] - This release of pledged shares represents 3.31% of the total share capital of the company [1]

| 股东名称 | 是否为控股 股东或第一 | | 本次解除质 押股份数量 | 占其所 持股份 | 占公司 总股本 | 质押起始 | | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 一致行动人 | | （股） | 比例(%) | 比例(%) | 日 | | | | | 罗欣控股 | | 是 | 36,020,000 | 15.20 | 3.31 | 2025 年 月 日 26 | 6 | 2025 年 11 月 日 4 | 浙江炳炳 典当有限 | | | | | | | | | | | 公司 | | 合计 | | - | 36,020,000 | 15.20 | 3.31 | - | | - | - | 一、股东股份解除质押的基本情况 证券代码：002793 股票简称：罗欣药业 公告编号：2025-101 罗欣药业集团股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 罗欣药业集团股份有限公司 ...

Core Viewpoint - The announcement details the release and pledge of shares by the controlling shareholder of Luoxin Pharmaceutical Group Co., Ltd., indicating no significant impact on the company's operations or governance [1]. Summary by Sections Share Pledge Release - The controlling shareholder, Shandong Luoxin Holdings Co., Ltd., has notified the company about the release and pledge of part of its shares [1]. - The total share capital is calculated based on 1,087,588,486 shares [5]. Share Pledge Situation - As of the announcement date, the controlling shareholder and its concerted parties, including Karamay Juezhi Equity Investment Management Partnership and Giant Star Global (HK) Limited, have pledged shares [1]. - The pledged shares are not related to significant asset restructuring or performance compensation obligations [1]. - There are no non-operating fund occupations or illegal guarantees that harm the interests of the listed company [1]. Impact on Company - The share pledge does not affect the company's production, governance, or performance compensation obligations [1]. - The pledged shares are not intended to meet the operational needs of the listed company [5]. - There are no pledged shares due to expire within the next year [5].

Core Viewpoint - The announcement from Luoxin Pharmaceutical indicates recent changes in the share pledging status of its controlling shareholder, Luoxin Holdings, which involves both the release and new pledging of shares without substantial impact on the company [1] Summary by Relevant Sections - **Share Pledge Release and New Pledge** - On October 31, Luoxin Holdings released a pledge of 102 million shares, accounting for 43.23% of its holdings and 9.42% of the company's total share capital [1] - On the same day, Luoxin Holdings pledged 101 million shares, representing 42.75% of its holdings and 9.31% of the company's total share capital [1] - **Cumulative Pledge Status** - As of the announcement date, Luoxin Holdings and its concerted parties have a total of 137 million pledged shares, which constitutes 56.83% of their holdings and 12.63% of the company's total share capital [1] - **Impact on the Company** - The current pledging activities are not intended to meet the operational needs of the listed company and are stated to have no substantial impact on the company [1]

证券代码：002793 股票简称：罗欣药业 公告编号：2025-100 | | | 注：总股本以公司截至目前股本总数1,087,588,486股为计算基数。质押股份不涉及负担重大 资产重组等业绩补偿义务。 罗欣药业集团股份有限公司 关于控股股东部分股份解除质押及质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 罗欣药业集团股份有限公司（以下简称"公司""本公司"）近日接到控股 股东山东罗欣控股有限公司（以下简称"罗欣控股"）的通知，获悉其所持有本 公司的部分股份被解除质押及质押，具体事项如下： 二、股东股份质押的基本情况 | 占其 | 占公 | 是否为控股 | 所持 | 司总 | 是否 | 是否为 | 质押 | 质押 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股东或第一 | 本次质押数 | 质权 | 质押 | 股份 | 股本 | 为限 | 补充质 | 起 ...

Core Viewpoint - 罗欣药业 is a key player in the pharmaceutical industry, focusing on research, production, and sales, with a notable presence in various market segments, including e-commerce and innovative medical concepts [1] Group 1: Business Performance - In Q3 2025, 罗欣药业 achieved a revenue of 1.723 billion yuan, ranking 38th among 110 companies in the industry, while the top company, 华东医药, reported a revenue of 32.664 billion yuan [2] - The net profit for the same period was 33.5591 million yuan, placing the company at 68th in the industry, with the leading company, 恒瑞医药, reporting a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, 罗欣药业's debt-to-asset ratio was 61.65%, an increase from 55.94% year-on-year, and significantly higher than the industry average of 35.26% [3] - The gross profit margin for the company was 51.77%, up from 42.81% year-on-year, but still below the industry average of 57.17% [3] Group 3: Executive Compensation - The chairman, 刘振腾, received a salary of 1.8672 million yuan in 2024, a slight decrease from 1.8796 million yuan in 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 3.53% to 38,300, while the average number of circulating A-shares held per shareholder increased by 3.66% to 28,400 [5] - Among the top ten circulating shareholders, 香港中央结算有限公司 ranked fifth, holding 30.3383 million shares, an increase of 15.1142 million shares from the previous period [5]

证券代码：002793 证券简称：罗欣药业 公告编号：2025-099 罗欣药业集团股份有限公司 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 罗欣药业集团股份有限公司（以下简称"公司"）及控股子公司对外担保总 额超过最近一期经审计净资产 100%；公司及控股子公司担保金额超过上市公司 最近一期经审计净资产 50%，提请投资者充分关注担保风险。 一、担保情况概述 为满足日常生产经营及业务拓展资金需要，保证生产经营持续发展和业务顺 利开展，公司拟为其控股子公司山东罗欣药业集团股份有限公司（以下简称"山 东罗欣"）人民币 11,000 万元银行授信额度提供担保。公司于 2025 年 1 月 14 日召开第五届董事会第二十一次会议及第五届监事会第十八次会议，分别以 6 票同意、0 票反对、0 票弃权及 4 票同意、0 票反对、0 票弃权的表决结果，审议 通过了《关于为控股子公司提供担保的议案》。具体内容详见公司于 2025 年 1 月 15 日刊登于巨潮资讯网（http://www.cninfo.com.cn）的《关 ...

Core Viewpoint - The stock price of Luoxin Pharmaceutical has experienced fluctuations, with a year-to-date increase of 34.82% but a recent decline of 6.19% over the past five trading days [2]. Company Performance - As of October 30, Luoxin Pharmaceutical's stock price was 5.15 CNY per share, with a market capitalization of 5.601 billion CNY [1]. - The company reported a revenue of 1.723 billion CNY for the period from January to September 2025, representing a year-on-year decrease of 8.37%. However, the net profit attributable to shareholders increased by 108.64% to 22.93 million CNY [2]. Shareholder Information - The number of shareholders increased by 26.23% to 48,300 as of October 20, 2025, while the average circulating shares per person decreased by 20.78% to 22,481 shares [2]. - Luoxin Pharmaceutical has distributed a total of 330 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Trading Activity - The stock has seen a net inflow of 462,700 CNY from main funds, with large orders accounting for 12.03% of total buying and 9.77% of total selling [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on July 31 [2]. Business Overview - Luoxin Pharmaceutical, established in May 1998 and listed in April 2016, is primarily engaged in the research, production, and sales of pharmaceutical products. Its main revenue sources include digestive system products (49.54%), antibiotics (22.12%), and other categories [2].